{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:46:08Z","timestamp":1777045568808,"version":"3.51.4"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Swedish Order of Freemason Foundation for Children"},{"name":"The Samariten Foundation"},{"DOI":"10.13039\/501100007373","name":"The Jerring Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007373","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Karolinska Institutet Funds","award":["2013tobi37895"],"award-info":[{"award-number":["2013tobi37895"]}]},{"DOI":"10.13039\/501100001862","name":"the Swedish Research Council","doi-asserted-by":"crossref","award":["2011-3440 and VR-Link 2012-3466"],"award-info":[{"award-number":["2011-3440 and VR-Link 2012-3466"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0181316","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T17:40:23Z","timestamp":1504892423000},"page":"e0181316","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin"],"prefix":"10.1371","volume":"12","author":[{"given":"Sandra","family":"Soeria-Atmadja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"\u00d6sterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars L.","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaran","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-0211","authenticated-orcid":true,"given":"Lars","family":"Nav\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"ref1","unstructured":"UNAIDS. AIDSinfo. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfounaidsorg\/\" xlink:type=\"simple\">http:\/\/aidsinfounaidsorg\/<\/ext-link>. 2014:Accessed May 18, 2016."},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/QAI.0b013e318235e560","article-title":"Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda","volume":"58","author":"Q Fillekes","year":"2011","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/135965350801300601","article-title":"A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations","volume":"13","author":"R ter Heine","year":"2008","journal-title":"Antivir Ther"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QAI.0b013e31805c9d52","article-title":"High prevalence of subtherapeutic plasma concentrations of efavirenz in children","volume":"45","author":"Y Ren","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00228-013-1634-1","article-title":"Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz","volume":"70","author":"P Naidoo","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"ES Group","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"D Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"ref8","article-title":"Middosing interval efavirenz plasma concentrations in HIV-1 infected children in Rwanda: treatment efficacy, tolerability, adherence and the influence of CYP2B6 polymorphisms","author":"PR Mutwa","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00228-011-1148-7","article-title":"Influence of CYP2B6 516G&gt;T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children","volume":"68","author":"M Viljoen","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"BA Ward","year":"2003","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"A Kwara","year":"2009","journal-title":"AIDS"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","article-title":"High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV\/AIDS patients","volume":"23","author":"M Swart","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"e67946","DOI":"10.1371\/journal.pone.0067946","article-title":"Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations","volume":"8","author":"E Ngaimisi","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans","volume":"68","author":"JK Mukonzo","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.10.94","article-title":"Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients","volume":"11","author":"L Elens","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s15010-013-0560-6","article-title":"Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism","volume":"42","author":"C Sukasem","year":"2014","journal-title":"Infection"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G&gt;T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"S Rodriguez-Novoa","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism","volume":"45","author":"A Saitoh","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bcp.12590","article-title":"Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa","volume":"80","author":"PZ Sinxadi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":"CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population","volume":"16","author":"RA Mirghani","year":"2006","journal-title":"Pharmacogenetics and genomics"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"HJ Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2012.00236","article-title":"ABCB1 4036A&gt;G and 1236C&gt;T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV\/AIDS Patients","volume":"3","author":"M Swart","year":"2012","journal-title":"Front Genet"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007691-200406000-00008","article-title":"Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects","volume":"26","author":"L Stahle","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12879-016-1381-x","article-title":"Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation","volume":"16","author":"F Pinillos","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/AAC.01738-13","article-title":"Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children","volume":"58","author":"AH Salem","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/135965350901400316","article-title":"Plasma efavirenz concentrations and the association with CYP2B6-516G &gt;T polymorphism in HIV-infected Thai children","volume":"14","author":"T Puthanakit","year":"2009","journal-title":"Antivir Ther"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1128\/AAC.02678-15","article-title":"Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years","volume":"60","author":"M Luo","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","author":"ER Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"F Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-13-261","article-title":"Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study","volume":"13","author":"JK Mukonzo","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/aid.2006.22.232","article-title":"Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy","volume":"22","author":"FV Leth","year":"2006","journal-title":"Aids Research and Human Retroviruses"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.01594-08","article-title":"Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?","volume":"53","author":"D Hirt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection\u2013What\u2019s new. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/appswhoint\/iris\/bitstream\/10665\/198064\/1\/9789241509893_engpdf?ua=1\" xlink:type=\"simple\">http:\/\/appswhoint\/iris\/bitstream\/10665\/198064\/1\/9789241509893_engpdf?ua=1<\/ext-link>. 2015;Accessed June 14, 2016."},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"e86919","DOI":"10.1371\/journal.pone.0086919","article-title":"Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes","volume":"9","author":"JK Mukonzo","year":"2014","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"I Usach","year":"2013","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"C Marzolini","year":"2001","journal-title":"Aids"},{"issue":"Suppl 2","key":"ref37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1293.2004.00227.x","article-title":"PENTA guidelines for the use of antiretroviral therapy, 2004","volume":"5","author":"M Sharland","year":"2004","journal-title":"HIV Med"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/00365548.2011.616223","article-title":"Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study","volume":"44","author":"LS Dalgaard","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"NM Laird","year":"1982","journal-title":"Biometrics"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1037\/0033-2909.104.3.396","article-title":"Heterogeneity of variance in experimental studies: A challenge to conventional interpretations","volume":"104","author":"AS Bryk","year":"1988","journal-title":"Psychological Bulletin"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/QAD.0000000000001463","article-title":"CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3\u201336 months with HIV infection","volume":"31","author":"C Bolton Moore","year":"2017","journal-title":"AIDS"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5414\/CPP40507","article-title":"Population pharmacokinetic meta-analysis with efavirenz","volume":"40","author":"JS Barrett","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.47.1.130-137.2003","article-title":"Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398","volume":"47","author":"M Pfister","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication","volume":"13","author":"W Stohr","year":"2008","journal-title":"Antivir Ther"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.spid.2003.09.004","article-title":"Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children","volume":"14","author":"DW Hoody","year":"2003","journal-title":"Semin Pediatr Infect Dis"},{"issue":"9","key":"ref46","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis","volume":"27","author":"Z Shubber","year":"2013","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0181316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T14:26:11Z","timestamp":1659450371000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0181316"}},"subtitle":[],"editor":[{"given":"Soraya","family":"Seedat","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0181316","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}